CD19-CART Treatment for ALL

Status Completed

Clinical Trial Summary

This study aims to evaluate the safety and efficacy of a novel CD19-CART in the treatment of refractory or recurrent ALL.

Clinical Trial Description

Chimeric antigen receptor T cell (CART) is a kind of engineered immunotherapy by transferring an artificial antigen binding receptor and also intercellular co-stimulating molecules into T cells. This kind of engineered T cells gains the ability to recognize antigen specific tumor cells and initiate the killing process in a HLA-independent way. CD19 is the specific cellular marker of B lineage acute leukemia (B-ALL), thus CD19-CART will be efficient in treating B lineage ALL. The investigators have constructed two kinds of CD19-CART. One is equipped with a murine CD19 scFv (single-chain variable fragmentt), while the other with a humanized scFv. This study aims to evaluate the safety and efficacy of both murine and humanized CD19-CART in treating refractory or recurrent ALL. ;

Study Design

Related Conditions & MeSH terms

Acute Leukemia

Clinical Trial Details

NCT number	NCT03232619
Study type	Interventional
Source	Shanghai Bioray Laboratory Inc.
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	August 1, 2018
Completion date	September 15, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05088356` - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft	Phase 1
Recruiting	`NCT04904588` - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide	Phase 2
Recruiting	`NCT04969601` - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings	Phase 1/Phase 2
Recruiting	`NCT02356159` - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation	Phase 1/Phase 2
Withdrawn	`NCT05170828` - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies	Phase 1
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Active, not recruiting	`NCT01956630` - Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT	Phase 1/Phase 2
Completed	`NCT00988013` - Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies	N/A
Enrolling by invitation	`NCT01728402` - Pathogenesis of Hematologic Malignancies
Active, not recruiting	`NCT03595800` - Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen	Phase 3
Completed	`NCT02440178` - Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia	Phase 2
Recruiting	`NCT05071482` - Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL	Phase 4
Withdrawn	`NCT03138395` - iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML	N/A
Completed	`NCT03042676` - Electronic Database for the Follow up of the ATG_FamilyStudy
Completed	`NCT04597086` - Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients	N/A
Terminated	`NCT03588936` - Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant	Phase 1
Recruiting	`NCT05521204` - Olverembatinib for FGFR1-rearranged Neoplasms	Phase 2
Not yet recruiting	`NCT04084327` - Immunophenotyping of Acute b Cell Lymphoblstic Leukemia
Terminated	`NCT00852709` - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias	Phase 1
Not yet recruiting	`NCT06026839` - Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors